Citations

Clear

1526 citation(s) found for "Sun, D".

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
Saper, Joel R., Silberstein, Stephen D., McCarville, Sally, Sun, Mark Y., Goadsby, Peter J. , Dodick, David W. , Goadsby, Peter J

Mayo Clinic

Cephalalgia | September 23, 2010 | Volume: 31 | Issue: 3 | Pages: 271-285

10.1177/0333102410381142 | PMID 20861241 Get It

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month. Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups. Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects. Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.
Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
Fouladi, Maryam , Stewart, Clinton F. , Gilbertson, Richard J. , Sun, Junfeng , Ames, Matthew M. , Speights, Roseanne, Ingle, Ashish M., Blaney, Susan M. , Adamson, Peter C. , Park, Julie R. , Schaiquevich, Paula S. , Reid, Joel M. , Zwiebel, James A.

Mayo Clinic

Journal of Clinical Oncology | July 7, 2010 | Volume: 28 | Issue: 22 | Pages: 3623-3629

10.1200/jco.2009.25.9119 | PMID 20606092 Get It

Purpose The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory solid tumors; to evaluate the tolerability of the solid tumor MTD in children with refractory leukemias; and to characterize the pharmacokinetics of a vorinostat suspension in children. Patients and Methods Vorinostat was administered orally daily starting at 180 mg/m2/d with escalations planned in 30% increments. Pharmacokinetic studies were performed with the initial dose. Acetyl-histone (H3) accumulation was assessed by Western blotting of peripheral blood mononuclear cells (PBMC). Results Sixty-four patients were enrolled on this multipart trial. In patients with solid tumors, the MTD was 230 mg/m2/d with dose-limiting neutropenia, thrombocytopenia, and hypokalemia at 300 mg/m2/d. DLTs observed with the combination of 13cRA and vorinostat included thrombocytopenia, neutropenia, anorexia, and hypertriglyceridemia, resulting in a MTD of vorinostat 180 mg/m2/d 4 times per week and 13cRA 80 mg/m2/dose twice per day, days 1 through 14 every 28 days. Wide interpatient variability was noted in vorinostat disposition, with area under the concentration-time curves at 230 mg/m2/d for the capsule (range, 1,415 to 9,291 ng/mL × hr) and oral suspension (range, 1,186 to 4,780 ng/mL × hr). Significant accumulation of acetylated H3 histone in PBMC was observed after administration of vorinostat, particularly at higher doses. One patient with neuroblastoma experienced a complete response to the combination. Conclusion In children with recurrent solid tumors, vorinostat is well-tolerated at 230 mg/m2/d, with a modest dose reduction being required when combining vorinostat with 13cRA. Drug disposition is similar to that observed in adults.
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
Ho, April J., Stein, Jason L. , Hua, Xue , Lee, Suh , Hibar, Derrek P., Leow, Alex , Dinov, Ivo D. , Toga, Arthur W. , Saykin, Andrew J. , Shen, Li , Pankratz, Nathan , Huentelman, Matthew J. , Craig, David W. , Gerber, Jill D., Allen, April N., Corneveaux, Jason J., Stephan, Dietrich A. , DeCarli, Charles , Dechairo, Bryan, Jack, Clifford R. , Weiner, Michael W. , Raji, Cyrus A. , Becker, James T. , Carmichael, Owen , Thompson, Paul M. , Initiative, the Alzheimer's Disease Neuroimaging, Thal, Leon J., Petersen, Ronald C., Jagust, William J. , Trojanowki, John Q., Toga, Arthur W., Gamst, Anthony, Potter, William Z., Montine, Tom, Anders, Dale, Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene E. , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Shaw, Les, Korecka, Magdalena , Toga, Arthur W., Crawford, Karen , Neu, Scott, Kornak, John , Kachaturian, Zaven, Frank, Richard , Molchan, Susan, Vorobik, Remi, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan , Fleisher, Adam , Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Badger, Beverly, Grossman, Hillel, deToledo‐Morrell, Leyla, Bach, Julie , Duara, Ranjan , Isaacson, Richard , Strauman, Silvia, Albert, Marilyn S. , Pedroso, Julia, Toroney, Jaimie, Santi, Susan M De, Doraiswamy, P. Murali , Petrella, Jeffrey R. , Aiello, Marilyn, Clark, Christopher M. , Pham, Cassie, Nuñez, Jessica, Smith, Charles D., Given, Curtis A., Hardy, Peter , DeKosky, Steven T. , Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem , McCallum, Colleen, Cramer, Steven C. , Mulnard, Ruth A., Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Laubinger, Mary M., Bartzokis, George, Lu, Po H. , Fletcher, Rita, Parfitt, Francine, Farlow, Martin R. , Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , MacAvoy, Martha G., Bifano, Laurel A., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Graham, Simon J. , Caldwell, Curtis, Assaly, Michele, Hsiung, Ging‐Yuek Robin , Kertesz, Andrew , Trost, Dick, Bernick, Charles , Johnson, Nancy , Sadowsky, Carl, Villena, Teresa, Mesner, Scott, Aisen, Paul, Johnson, Kathleen, Behan, Kelly E., Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Ashford, Wes, Connor, Donald J., Obradov, Sanja, Jayam‐Trouth, Annapurni , Wang, Paul J. , Auchus, Alexander P. , Huang, Juebin , DeCarli, Charles , Kittur, Smita, Mirje, Seema, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Highum, Diane, Preda, Adrian , Tariot, Pierre N. , Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Gandy, Sam, Marenberg, Marjorie E., Rovner, Barry W. , Blank, Karen, Anderson, Karen, Santulli, Robert B. , Paré, Nadia, Williamson, Jeff D. , Raj, Balebail Ashok, Giordano, Amy T., Ott, Brian R. , Wu, Chuang‐Kuo, Cohen, Ronald A. , Wilks, Kerri, Lee, Ting‐Yim , Foroud, Tatiana , Potkin, Steven G. , López, Oscar L. , Initiative, the Alzheimer's Disease Neuroimaging, Toga, Arthur W., Beckett, Laurel , Green, Robert C. , Bernstein, Matt A. , Fox, Nick C. , Koeppe, Robert A. , Foster, Norm, Chen, Kewei , Lee, Virginia M.‐Y. , Toga, Arthur W., Harvey, Danielle , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Morris, John C. , Tang, Cheuk Ying , Stern, Jessica A. , Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Porsteinsson, Anton P. , Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Black, Sandra E. , Feldman, Howard , ROGERS, John H. , Gitelman, Darren R. , Mesulam, Marsel M. , Sperling, Reisa Anne , Rentz, Dorene M. , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Friedland, Robert P. , Fletcher, Evan M. , Johnson, Sterling C. , Nguyen, Dana R. , Scharre, Douglas W. , Beversdorf, David Q. , Gandy, Sam , Pearlson, Godfrey D. , Sink, Kaycee M. , Potter, Huntington , Jack, Clifford R , Saykin, Andrew J , Shen, Li , Preda, Adrian , Toga, Arthur W , Stein, Jason L , Thompson, Paul M , Hsiung, Gink-Yuek , Pankratz, Nathan

Mayo Clinic

Proceedings of the National Academy of Sciences | April 19, 2010 | Volume: 107 | Issue: 18 | Pages: 8404-8409

10.1073/pnas.0910878107 | PMID 20404173 Get It

A recently identified variant within the fat mass and obesity-associated ( FTO ) gene is carried by 46% of Western Europeans and is associated with an ~1.2 kg higher weight, on average, in adults and an ~1 cm greater waist circumference. With >1 billion overweight and 300 million obese persons worldwide, it is crucial to understand the implications of carrying this very common allele for the health of our aging population. FTO is highly expressed in the brain and elevated body mass index (BMI) is associated with brain atrophy, but it is unknown how the obesity-associated risk allele affects human brain structure. We therefore generated 3D maps of regional brain volume differences in 206 healthy elderly subjects scanned with MRI and genotyped as part of the Alzheimer's Disease Neuroimaging Initiative. We found a pattern of systematic brain volume deficits in carriers of the obesity-associated risk allele versus noncarriers. Relative to structure volumes in the mean template, FTO risk allele carriers versus noncarriers had an average brain volume difference of ~8% in the frontal lobes and 12% in the occipital lobes—these regions also showed significant volume deficits in subjects with higher BMI. These brain differences were not attributable to differences in cholesterol levels, hypertension, or the volume of white matter hyperintensities; which were not detectably higher in FTO risk allele carriers versus noncarriers. These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly.
Direct visualization of deep brain stimulation targets in Parkinson disease with the use of 7-tesla magnetic resonance imaging
Cho, Zang‐Hee , Min, Hoon‐Ki , Oh, Se‐Hong , Han, Jae-Yong, Park, Chan-Woong, Chi, Je-Geun, Kim, Young-Bo , Paek, Sun Ha , Lozano, Andrés M. , Lee, Kendall H. , Min, Hoon-Ki Paul

Mayo Clinic

Journal of Neurosurgery | April 9, 2010 | Volume: 113 | Issue: 3 | Pages: 639-647

10.3171/2010.3.jns091385 | PMID 20380532 Get It

Object A challenge associated with deep brain stimulation (DBS) in treating advanced Parkinson disease (PD) is the direct visualization of brain nuclei, which often involves indirect approximations of stereotactic targets. In the present study, the authors compared T2*-weighted images obtained using 7-T MR imaging with those obtained using 1.5- and 3-T MR imaging to ascertain whether 7-T imaging enables better visualization of targets for DBS in PD. Methods The authors compared 1.5-, 3-, and 7-T MR images obtained in 11 healthy volunteers and 1 patient with PD. Results With 7-T imaging, distinct images of the brain were obtained, including the subthalamic nucleus (STN) and internal globus pallidus (GPi). Compared with the 1.5- and 3-T MR images of the STN and GPi, the 7-T MR images showed marked improvements in spatial resolution, tissue contrast, and signal-to-noise ratio. Conclusions Data in this study reveal the superiority of 7-T MR imaging for visualizing structures targeted for DBS in the management of PD. This finding suggests that by enabling the direct visualization of neural structures of interest, 7-T MR imaging could be a valuable aid in neurosurgical procedures.
Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy
Moyer, Ann M. , Sun, Zhifu , Batzler, Anthony , Schaid, Daniel J. , Weinshilboum, Richard M. , Li, Liang , Yang, Ping , Weinshilboum, Richard M. , Sun, Zhifu

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 9, 2010 | Volume: 19 | Issue: 3 | Pages: 811-821

10.1158/1055-9965.epi-09-0871 | PMID 20200426 Get It

Abstract Background: Lung cancer is commonly treated with platinum compounds. The “glutathione pathway” participates in the metabolism of platinum compounds. We set out to test the hypotheses that single nucleotide polymorphisms (SNPs) or copy number polymorphisms for genes within the glutathione pathway might influence survival in lung cancer patients treated with these drugs. Methods: Germline DNA samples from 973 lung cancer patients were genotyped for 290 glutathione pathway SNPs. GSTT1 copy number was also assayed. We determined the association of these polymorphisms with survival for lung cancer patients, followed by functional genomic validation. Results: We observed suggestive associations between survival and GSTT1 copy number (P = 0.017), and GSTA5, GSTM4, and ABCC4 SNPs, adjusted for covariates (P = 0.018, 0.002, and 0.002, respectively) or not (P = 0.005, 0.011, and 0.002). One hundred lymphoblastoid cell lines were then treated with cisplatin, and IC50 values were significantly associated with the GSTM4 SNP (P = 0.019). Furthermore, GSTM4, GSTT1, and ABCC4 overexpression significantly decreased cisplatin sensitivity in lung cancer and HEK293T cell lines. Conclusions: These results suggest that GSTM4 polymorphisms are biomarkers for the prediction of cisplatin response. ABCC4 polymorphisms, as well as GSTT1 copy number, may also help to predict cisplatin response, but further validation is required. These results represent a step toward the individualized chemotherapy of lung cancer. Cancer Epidemiol Biomarkers Prev; 19(3); 811–21
The Relationship Between Smoking and Replicated Sequence Variants on Chromosomes 8 and 9 With Familial Intracranial Aneurysm
Deka, Ranjan , Koller, Daniel L., Indugula, Subba Rao , Sun, Guangyun, Woo, Daniel , Sauerbeck, Laura, Moomaw, Charles J. , Hornung, Richard, Connolly, E. Sander , Anderson, Craig S. , Meissner, Irene, Bailey‐Wilson, Joan E. , Brown, Robert D., Kleindorfer, Dawn , Flaherty, Matthew L. , Langefeld, Carl D. , Investigators, the FIA Study, Derdeyn, Colin P. , Lai, Dongbing , Rouleau, Guy Armand , Huston, John , Foroud, Tatiana , Broderick, Joseph P. , Investigators, the FIA Study, Wilson, Richard K , Derdeyn, Colin P

Mayo Clinic

Stroke | February 27, 2010 | Volume: 41 | Issue: 6 | Pages: 1132-1137

10.1161/strokeaha.109.574640 | PMID 20190001 Get It

Background and Purpose— The purpose of this study was to replicate the previous association of single nucleotide polymorphisms (SNPs) with risk of intracranial aneurysm (IA) and to examine the relationship of smoking with these variants and the risk of IA. Methods— White probands with an IA from families with multiple affected members were identified by 26 clinical centers located throughout North America, New Zealand, and Australia. White control subjects free of stroke and IA were selected by random digit dialing from the Greater Cincinnati population. SNPs previously associated with IA on chromosomes 2, 8, and 9 were genotyped using a TaqMan assay or were included in the Affymetrix 6.0 array that was part of a genomewide association study of 406 IA cases and 392 control subjects. Logistic regression modeling tested whether the association of replicated SNPs with IA was modulated by smoking. Results— The strongest evidence of association with IA was found with the 8q SNP rs10958409 (genotypic P =9.2×10 −5 ; allelic P =1.3×10 −5 ; OR=1.86, 95% CI: 1.40 to 2.47). We also replicated the association with both SNPs on chromosome 9p, rs1333040 and rs10757278, but were not able to replicate the previously reported association of the 2 SNPs on chromosome 2q. Statistical testing showed a multiplicative relationship between the risk alleles and smoking with regard to the risk of IA. Conclusion— Our data provide complementary evidence that the variants on chromosomes 8q and 9p are associated with IA and that the risk of IA in patients with these variants is greatly increased with cigarette smoking.
Paracrine interactions among parathyroid cells: Effect of cell density on cell secretion
Sun, Feng , Maercklein, Peter B., Fitzpatrick, Lorraine A.

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 9 | Issue: 7 | Pages: 971-976

10.1002/jbmr.5650090703 | PMID 7942165 Get It

Abstract Cell-cell interactions are important in the regulation of endocrine cell secretion. To investigate the possibility that cell communication may alter the regulation of parathyroid cell secretion, we utilized the reverse hemolytic plaque assay (RHPA) to measure parathyroid hormone (PTH) release from individual cells. Bovine parathyroid cells were dispersed and plated with protein A-conjugated erythrocytes at cell densities ranging from 0.9 to 36 X 102 cells/cm2 in 0.2 mM calcium. Cell populations were greater than 98% homogeneous as determined by immunocytochemistry and in situ hybridization for PTH mRNA. Plaques were developed and data analyzed for the amount of PTH per cell released (plaque area in μm2 X 104) and the determination of cell recruitment (% plaques formed). A positive correlation existed between parathyroid cell density and the amount of PTH released. As the distance between cells increased, the plaque area (amount of PTH released per cell) decreased (ranging from 1.0 X 1044 μm2 at 0.9 X 102 cells/cm2 versus 1.6 X 104 μm2 at 36 X 102 cells/cm2). The percentage of cells releasing PTH (recruitment) also decreased (16% at 0.9 X 102 cells/cm2 versus 47% at 36 X 102 cells/cm2). These data suggest that parathyroid cells in close proximity are stimulated to secrete more hormone than those at lesser densities. In addition, parathyroid cells are recruited to secrete PTH when plated at high density. Factor(s) released by the parathyroid cell may increase cell responsiveness and stimulate secretion in a paracrine fashion.
Olfaction in the Elderly: A Cross-Sectional Analysis Comparing Parkinson's Disease with Controls and Other Disorders
McKinnon, Jonathan H., Evidente, Virgilio Gerald H. , Driver‐Dunckley, Erika , Premkumar, Ashvini P., Hentz, Joseph G. , Shill, Holly A. , Sabbagh, Marwan, Caviness, John N., Connor, Donald J., Adler, Charles H.

Mayo Clinic

International Journal of Neuroscience | February 3, 2010 | Volume: 120 | Issue: 1 | Pages: 36-39

10.3109/00207450903428954 | PMID 20128670 Get It

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, Mark R. , Tarima, Sergey , Pérez, Waleska S., Bolwell, Brian J., Cairo, Mitchell S. , Camitta, Bruce M., Luger, Selina M. , Marks, David I. , Pasquini, Marcelo C. , Phillips, Gordon L., Rizzo, J. Douglas , Sierra, Jorge , Tallman, Martin S. , Weisdorf, Daniel J. , Cutler, Corey S. , Lima, Marcos de , DiPersio, John F. , Gale, Robert Peter , Keating, Armand , Lazarus, Hillard M. , Maziarz, Richard Thomas , McCarthy, Philip L. , Weisdorf, Dan

Mayo Clinic

Blood | December 24, 2009 | Volume: 115 | Issue: 9 | Pages: 1850-1857

10.1182/blood-2009-10-249128 | PMID 20032503 Get It

Abstract Therapy-related myelodysplastic syndromes (t-MDSs) and acute myeloid leukemia (t-AML) have a poor prognosis with conventional therapy. Encouraging results are reported after allogeneic transplantation. We analyzed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. A myeloablative regimen was used for conditioning in 77%. Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively. Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P < .001). These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation.
Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy
Saloura, Vassiliki , Wang, Liang‐Chuan S., Fridlender, Zvi G., Sun, Jing , Cheng, Guanjun, Kapoor, Veena, Sterman, Daniel H. , Harty, Ronald N. , Okumura, Atsushi , Barber, Glen N. , Vile, Richard G. , Federspiel, Mark J. , Russell, Stephen J. , Litzky, Leslie A., Albelda, Steven Μ. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy | August 28, 2009 | Volume: 21 | Issue: 1 | Pages: 51-64

10.1089/hum.2009.088 | PMID 19715403 Get It